dcterms.isReferencedBy |
Michielsen, P.P., Francque, S.M., van Dongen, J.L., Viral hepatitis and hepatocellular carcinoma (2005) World J Surg Oncol, 3, p. 27; Altekruse, S.F., McGlynn, K.A., Reichman, M.E., Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005 (2009) J Clin Oncol, 27 (9), pp. 1485-1491; Chang, M.H., Chen, T.H., Hsu, H.M., Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: The effect and problems (2005) Clin Cancer Res, 11 (21), pp. 7953-7957; Pardee, A.D., Butterfield, L.H., Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities (2012) Oncoimmunology, 1 (1), pp. 48-55; Buonaguro, L., Petrizzo, A., Tagliamonte, M., Tornesello, M.L., Buonaguro, F.M., Challenges in cancer vaccine development for hepatocellular carcinoma (2013) J Hepatol, 59 (4), pp. 897-903; Forni, G., Lollini, P.L., Musiani, P., Colombo, M.P., Immunoprevention of cancer: Is the time ripe? (2000) Cancer Res, 60 (10), pp. 2571-2575; Kimura, T., McKolanis, J.R., Dzubinski, L.A., MUC1 vaccine for individuals with advanced adenoma of the colon: A cancer immunoprevention feasibility study (2013) Cancer Prev Res (Phila), 6 (1), pp. 18-26; Vollmer Jr., C.M., Eilber, F.C., Butterfield, L.H., Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma (1999) Cancer Res, 59 (13), pp. 3064-3067; Chu, P.G., Ishizawa, S., Wu, E., Weiss, L.M., Hepatocyte antigen as a marker of hepatocellular carcinoma: An immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein (2002) Am J Surg Pathol, 26 (8), pp. 978-988; Fujioka, M., Nakashima, Y., Nakashima, O., Kojiro, M., Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma (2001) Hepatology, 34 (6), pp. 1128-1134; Lavaissiere, L., Jia, S., Nishiyama, M., Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma (1996) J Clin Invest, 98 (6), pp. 1313-1323; Shimoda, M., Tomimaru, Y., Charpentier, K.P., Safran, H., Carlson, R.I., Wands, J., Tumor progression-related transmembrane protein aspartate-beta-hydroxylase is a target for immunotherapy of hepatocellular carcinoma (2012) J Hepatol, 56 (5), pp. 1129-1135; Komori, H., Nakatsura, T., Senju, S., Identification of HLA-A2-or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma (2006) Clin Cancer Res, 12 (9), pp. 2689-2697; Wang, Y., Han, K.J., Pang, X.W., Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies (2002) J Immunol, 169 (2), pp. 1102-1109; Li, B., Wang, Y., Chen, J., Wu, H., Chen, W., Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587 (2005) Clin Exp Immunol, 140 (2), pp. 310-319; Ge, L., Zhang, J.G., Samathanam, C.A., Cytotoxic T cell immunity against the non-immunogenic, murine, hepatocellular carcinoma Hepa1-6 is directed towards the novel alternative form of macrophage colony stimulating factor (2009) Cell Immunol, 259 (2), pp. 117-127; Covini, G., Chan, E.K., Nishioka, M., Morshed, S.A., Reed, S.I., Tan, E.M., Immune response to cyclin B1 in hepatocellular carcinoma (1997) Hepatology, 25 (1), pp. 75-80; Shao, D.M., Wang, Q.H., Chen, C., N-acetylglucosaminyltransferase V activity in metastatic models of human hepatocellular carcinoma in nude mice (1999) J Exp Clin Cancer Res, 18 (3), pp. 331-335; Bricard, G., Bouzourene, H., Martinet, O., Naturally acquired MAGE-A10-and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma (2005) J Immunol, 174 (3), pp. 1709-1716; Chen, Z., Shao, J.B., Wu, W., Expression of A, G and B melanoma antigen genes in human hepatocellular carcinoma (2002) Hepatobiliary Pancreat Dis Int, 1 (4), pp. 570-573; Nies, A.T., Konig, J., Pfannschmidt, M., Klar, E., Hofmann, W.J., Keppler, D., Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma (2001) Int J Cancer, 94 (4), pp. 492-499; Luo, G., Huang, S., Xie, X., Expression of cancer-testis genes in human hepatocellular carcinomas (2002) Cancer Immun, 2, p. 11; Mizukoshi, E., Nakamoto, Y., Marukawa, Y., Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma (2006) Hepatology, 43 (6), pp. 1284-1294; Ikeguchi, M., Ueda, T., Sakatani, T., Hirooka, Y., Kaibara, N., Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma (2002) Diagn Mol Pathol, 11 (1), pp. 33-40; Perugorria, M.J., Castillo, J., Latasa, M.U., Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy (2009) Cancer Res, 69 (4), pp. 1358-1367; Zhang, J.G., Eguchi, J., Kruse, C.A., Antigenic profiles of glioma cells to generate allogeneic vaccines or DC-based therapeutics (2007) Clin Cancer Res, 13, pp. 566-575; Ge, L., Cornforth, A.N., Hoa, N.T., Differential glioma-associated tumor antigen expression profiles of human glioma cells grown in hypoxia (2012) PLoS One, 7 (9), pp. e42661; Agrawal, S., Gupta, S., Agrawal, A., Human dendritic cells activated via dectin-1 are efficient at priming Th17, cytotoxic CD8 T and B cell responses (2010) PLoS One, 5 (10), pp. e13418; Gordan, J.D., Vonderheide, R.H., Universal tumor antigens as targets for immunotherapy (2002) Cytotherapy, 4 (4), pp. 317-327; Cheever, M.A., Allison, J.P., Ferris, A.S., The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research (2009) Clin Cancer Res, 15 (17), pp. 5323-5337; Gulley, J.L., Drake, C.G., Immunotherapy for prostate cancer: Recent advances, lessons learned, and areas for further research (2011) Clin Cancer Res, 17 (12), pp. 3884-3891; Prins, R.M., Soto, H., Konkankit, V., Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy (2011) Clin Cancer Res, 17 (6), pp. 1603-1615; Pardoll, D., Drake, C., Immunotherapy earns its spot in the ranks of cancer therapy (2012) J Exp Med, 209 (2), pp. 201-209; Couzin-Frankel, J., Immune therapy steps up the attack (2010) Science, 330 (6003), pp. 440-443; Lee, W.C., Wang, H.C., Hung, C.F., Huang, P.F., Lia, C.R., Chen, M.F., Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: A clinical trial (2005) J Immunother, 28 (5), pp. 496-504; Bird, A.W., Hyman, A.A., Building a spindle of the correct length in human cells requires the interaction between TPX2 and Aurora A (2008) J Cell Biol, 182 (2), pp. 289-300; Warner, S.L., Stephens, B.J., Nwokenkwo, S., Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells (2009) Clin Cancer Res, 15 (21), pp. 6519-6528; Ma, Y., Lin, D., Sun, W., Expression of targeting protein for xklp2 associated with both malignant transformation of respiratory epithelium and progression of squamous cell lung cancer (2006) Clin Cancer Res, 12 (4), pp. 1121-1127; Tanaka, S., Arii, S., Yasen, M., Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy (2008) Br J Surg, 95 (5), pp. 611-619; Yang, C.W., Su, J.Y., Tsou, A.P., Integrative genomics based identification of potential human hepatocarcinogenesis-associated cell cycle regulators: RHAMM as an example (2005) Biochem Biophys Res Commun, 330 (2), pp. 489-497; Satow, R., Shitashige, M., Kanai, Y., Combined functional genome survey of therapeutic targets for hepatocellular carcinoma (2010) Clin Cancer Res, 16 (9), pp. 2518-2528 |
|